November 15, 2019

November 15, 2019

Subscribe to Latest Legal News and Analysis

November 14, 2019

Subscribe to Latest Legal News and Analysis

November 13, 2019

Subscribe to Latest Legal News and Analysis

EC Committee Publishes Guidance on Safety Assessment of Nanomaterials in Cosmetics

On November 4, 2019, the European Commission’s (EC) Scientific Committee on Consumer Safety (SCCS) published an updated Guidance on the Safety Assessment of Nanomaterials in Cosmetics.  The Guidance updates SCCS’s 2012 Guidance (SCCS/1484/12) on the safety assessment of nanomaterials in cosmetic products.  It covers the main elements of safety assessment — general considerations (Section 2), material characterization (Section 3), exposure assessment (Section 4), hazard identification and dose-response characterization (Section 5), and risk assessment (Section 6).  The Guidance includes key recommendations for the safety assessment of nanomaterials intended for use in cosmetics on the following topics:

  • Definition: The regulatory definition of nanomaterial is provided in the Cosmetic Regulation (EC) No. 1223/2009, under Article 2(1)(k).  SCCS suggests that when assessing the safety of a material consisting of small particles, applicants should also take into account the EC’s Recommendation (2011/696/EU).  SCCS notes that “[w]here a new or an already-approved cosmetic ingredient fulfils the criteria for defining it as NM, it will be subject to safety assessment based on the data relevant to nano-scale properties.”

  • Material characterization: At a minimum, applicants must provide characterization data on all the specified parameters that are relevant to a given nanomaterial.  According to the Guidance, the nanomaterial characterization needs to be carried out at the raw material stage, in the cosmetic formulation, and during exposure for toxicological evaluations.  The Guidance notes that SCCS may request a detailed description of the production processes, any surface modifications, and the preparatory steps carried out for integrating the nanomaterials in the final cosmetic products as input into the safety assessment process.

  • Exposure assessment: Safety assessment of nanomaterials follows the same procedure as for non-nanoscale ingredients, but with special considerations of the nanoscale aspects.  According to the Guidance, SCCS is of the view that the method for calculating dermal and oral exposure to nanomaterials will not be substantially different from the calculation of exposure to conventional cosmetic ingredients.  The Guidance notes that calculation of exposure to aerosols containing nanomaterials may be more challenging, however.

  • Hazard identification/dose-response characterization: SCCS will require data from toxicological studies for local and — in case of systemic absorption — systemic effects.  According to the Guidance, testing of nanomaterials for hazard identification/dose-response characterization must be carried out in consideration of the nano-related aspects.

  • Safety assessment: The Guidance notes that historically, calculation of the margin of safety of a cosmetic ingredient has been based on a measured toxicological point of departure (POD), along with an estimate of internal exposure in terms of systemic exposure dose (SED).  The Guidance acknowledges that with the European Union’s ban on animal testing of cosmetic ingredients and/or products, derivation of PODsys for systemic adverse effects of a new cosmetic ingredient may not be possible, or possible only in exceptional cases.  Data obtained to comply with other non-cosmetic regulations should be used and submitted when available, however.  For other cases, the applicant will need to assemble relevant information and data from different alternative (non-animal) methods and integrate the data to build an overall weight of evidence to support the safety of the cosmetic ingredient.

SCCS notes that due to the evolving nature of nanomaterials safety research, it may revise the Guidance in the future to take account of any new scientific knowledge.

©2019 Bergeson & Campbell, P.C.

TRENDING LEGAL ANALYSIS


About this Author

Carla Hutton, Bergeson Campbell PC, global regulatory attorney, public health activists lawyer, metals industry legal counsel, Toxic Substances Control Act law
Regulatory Analyst

Since 1996, Carla Hutton has monitored, researched, and written about regulatory and legislative issues that may potentially affect Bergeson & Campbell, P.C. (B&C®) clients. She is responsible for creating a number of monthly and quarterly regulatory updates for B&C's clients, as well as other documents, such as chemical-specific global assessments of regulatory developments and trends. She authors memoranda for B&C clients on regulatory and legislative developments, providing information that is focused, timely and applicable to client...

202-557-3809
Lynn Bergeson, Campbell PC, Toxic Substances Control Act Attorney, federal insecticide lawyer, industrial biotechnology legal counsel, Food Drug Administration law
Managing Partner

Owner of Bergeson & Campbell, P.C. (B&C®), Lynn L. Bergeson has earned an international reputation for her deep and expansive understanding of the Toxic Substances Control Act (TSCA), the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), European Union Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), and especially how these regulatory programs pertain to nanotechnology, industrial biotechnology, synthetic biology, and other emerging transformative technologies. Her knowledge of and involvement in the policy process allows her to develop client-focused strategies whether advocating before Congress, the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), or other governance and standard-setting bodies.

Ms. Bergeson counsels corporations, trade associations, and business consortia on a wide range of issues pertaining to chemical hazard, exposure and risk assessment, risk communication, minimizing legal liability, and evolving regulatory and policy matters pertinent to conventional, biobased, and nanoscale chemicals, particularly with respect to TSCA, FIFRA, Food Quality Protection Act (FQPA), REACH and REACH-like programs, and Occupational Safety and Health Administration (OSHA) matters.

202-557-3801